Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 23, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director or Manager (PDMR), rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to a specific securities transaction notification.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction involving the acquisition of 1 American Depositary Share (ADS) by Dr. K. Slaoui, a PCA of Dr. M. M. Slaoui (Chairman, Global Vaccines).
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. The transaction was an increase of 1 ADS following the notional allocation of ADSs on August 22, 2016, at a price of $44.12 per ADS, resulting from the revaluation of the cash element of the notional investment held within the GSK 401(K) plan.
Investor Verification Checklist
- Verify the identity of Dr. K. Slaoui as a PCA of Dr. M. M. Slaoui.
- Confirm the transaction date of August 22, 2016, and the execution price of $44.12 per ADS.
- Note that this filing does not contain quarterly or annual financial performance data.